Possible Impact of a European Agency for the Strategic Management Against Cancer (EASMAC) on Treatment, Diagnosis and EU Politics

Abstract

Each European Union (EU) country has its own therapeutic and diagnostic protocols for cancer treatment, contrary to the USA. In order to achieve a therapeutic and follow-up harmonization, the existence of a central EU agency can be of paramount importance. The aim of the current paper is to present the (still in paper) European Agency for the Strategic Management Against Cancer (EASMAC) and its possible impact on cancer patient treatment and diagnosis and EU politics in general.